Dr. Kinsey’s primary clinical responsibilities are in Gastrointestinal Medical Oncology. He initially set out on the path to become a physician-scientist by conducting undergraduate research at Bucknell University studying Osteosarcoma. During his Medical Scientist Training Program training at the University of Rochester he was mentored by Hartmut K. Land PhD investigating the role of PLAC8 in autophagy and gastrointestinal malignancies. The major emphasis of his recent research has been to discover new therapeutic opportunities for pancreatic cancer with the combination of MAP Kinase signaling inhibition and autophagy inhibition. This has resulted in two clinical trials targeting MEK/ERK and autophagy in RAS mutated gastrointestinal malignancies of which Dr. Kinsey is the Primary Investigator.
Precision medicine has incredible promise for patients. Enormous amounts of money and time are invested in developing technologies and targeted therapies. Genomics, proteomics, phosphorylation assays, RNA expression, organoid growth, and testing, and even delicate mass measurement of liquid cancer cells are explored. This innovation must be focused to maximize the benefit to the most important participants in our healthcare system, the patient. This track is about putting patient needs first, and understanding and accessing the latest (cancer) treatment options.